

MEDICARE FORM

Signifor LAR (pasireotide) **Medication Precertification Request**

Page 1 of 2

(All fields must be completed and legible for precertification review.)

For Illinois MMP: **FAX:** 1-855-320-8445 PHONE: 1-866-600-2139

For other lines of business:

Please use other form

Note: Signifor LAR is nonpreferred for acromegaly. The preferred products are Sandostatin LAR and Somatuline

Please indicate:		·				Depot.	
			f last treatment				
				Pnone	:	Fax:	
A. PATIENT INFORM	IATION		Lead Marie			DOD	
First Name:			Last Name:	T		DOB:	T
Address:		I		City:		State:	ZIP:
Home Phone:		Work Phone:		Cell Phone:	1	Email:	
		kgs Patier	nt Height: inches	or cms	Allergies:		
B. INSURANCE INFO	DRMATION						
Aetna Member ID #:			Does patient have other coverage?				
Group #:			If yes, provide ID#: Insured:		Carrier Name:		
	7 N. 16	- ID #.		dissid. \square V.s.	□ No. 16	: ID #:	
Medicare: Yes		e ID #:	IVIE	edicald: Yes	☐ No If yes, prov	vide ID #:	
C. PRESCRIBER INF First Name:	ORMATION		Last Name:		(Check C)ne): □ M D □	☐ D.O. ☐ N.P. ☐ P.A
Address:			Last Name.	City:	(Crieck C	State:	ZIP:
Phone:	Fax:		St Lic #:	NPI #:	DEA #:	State.	UPIN:
	rax:				DEA #:	In.	UPIN:
Provider Email:			Office Contact Name:		Phone:		
Specialty (Check one): Endocrinolo	gist 🗌 Other	<u></u>				_
☐ Outpatient Infusion Center Name: ☐ Home Infusion Cen Agency Name ☐ Administration code Address: City: Phone: TIN: NPI: E. PRODUCT INFOR	ter Pho :: e(s) (CPT): F	State:	ZIP:	Name: Address: City: Phone: TIN:		State: Fax: PIN:	
Request is for: Si	gnifor LAR (pasire	eotide) Dose: _		Frequency:	I		
F. DIAGNOSIS INFO	RMATION - Please	e indicate primar	y ICD code and specify	any other where	e applicable.		
Primary ICD Code:]		_ Secondary ICD Cod	de :	Other	ICD Code:	
G. CLINICAL INFOR	MATION - Require	d clinical informa	ation must be complete	d in its <u>entirety</u> fo	or all precertification	requests.	
Yes No Has th Yes No Has th Please explain if there diagnosis? (select all the	non-preferred for a e patient had prior the e patient had a trial Sandostatin LAR (od are any other medicated apply)	ncromegaly. The nerapy with Signi and failure, intole treotide acetate) al reason(s) that	for all requests): preferred products are for LAR within the last 36 erance, or contraindicatio Somatuline Depot (I the patient cannot use a	35 days? In to any of the foll lanreotide) ny of the following	lowing? (select all th	at apply)	for the patient's

Continued on next page



MEDICARE FORM

Signifor LAR (pasireotide) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

For Illinois MMP:

FAX: 1-855-320-8445 **PHONE:** 1-866-600-2139

For other lines of business:

Please use other form

Note: Signifor LAR is nonpreferred for acromegaly. The preferred products are Sandostatin LAR and Somatuline Depot.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
G. CLINICAL INFORMATION (continued) – Required clinical information	n must be completed in its <u>entirety</u> for all pr	ecertification requests.
☐ Acromegaly			
Please indicate the patient's	pretreatment IGF-1 (insulin-like growth fac	ctor 1) level compared to the laboratory's re	eference normal range based on age
and/or gender:	vel is higher than the laboratory's normal ra	ange 🔲 IGF-1 level is lower than the labo	oratory's normal range
☐ IGF-1 le	vel falls within the laboratory's normal rang	je	
	ent had an inadequate or partial response		
└─── ☐ Yes ☐	No Is there a clinical reason why the patie	ent has not had surgery?	
☐ Cushing's syndrome/disea	se		
☐ Yes ☐ No Did the patie	ent have surgery that was not curative?		
└─── ☐ Yes ☐	No Is the patient a candidate for surgery?	?	
For Continuation Requests (cli	nical documentation required for all rec	quests):	
☐ Acromegaly only:			
<u> </u>	ent's IGF-1 (insulin-like growth factor 1) le	.,	
☐ IGF-1 level has increased	I ☐ IGF-1 level has decreased or norma	lized	
H. ACKNOWLEDGEMENT			
Request Completed By (Sign	nature Required):		Date:/ /
insurance company by provice		nceals material information for the purp	the intent to injure, defraud or deceive any lose of misleading, commits a fraudulent

The plan may request additional information or clarification, if needed, to evaluate requests.